Inotuzumab Ozogamicin (Inonza)
Inotuzumab Ozogamicin Injection (Inonza) is an advanced targeted therapy used in the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This monoclonal antibody-drug conjugate specifically binds to CD22-positive cancer cells, delivering a cytotoxic agent directly to malignant cells while minimizing damage to healthy tissues. Designed for improved therapeutic outcomes, it supports better remission rates in patients who have not responded to conventional treatments. Administered under medical supervision, it offers a promising option in oncology care. Ensure proper dosage and follow prescribed guidelines for optimal effectiveness and safety during treatment.
Description
Inotuzumab Ozogamicin (Inonza) delivers a highly targeted approach for treating relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This advanced therapy combines a monoclonal antibody with a potent cytotoxic agent to directly attack cancer cells. It specifically recognizes and binds to CD22 antigens expressed on malignant B-cells, allowing precise delivery of the drug into the cancerous cells. By focusing on diseased cells, it helps reduce damage to healthy tissues and improves treatment outcomes.
Doctors prescribe this medication for patients who have not responded adequately to conventional chemotherapy. It works by entering the cancer cells after binding to CD22, where it releases the active cytotoxic compound. This process disrupts DNA and leads to cell death, effectively reducing the number of leukemia cells in the body. As a result, patients may achieve better remission rates and improved disease control.
Healthcare professionals administer this injection through intravenous infusion under strict medical supervision. They carefully determine the dosage based on the patient’s condition, body response, and treatment plan. Regular monitoring helps manage potential side effects and ensures the therapy delivers optimal results. Patients should always follow their doctor’s instructions and attend scheduled check-ups during treatment.
This therapy represents a significant advancement in oncology by offering a more precise and effective option for difficult-to-treat leukemia cases. It provides hope for patients seeking improved outcomes after standard treatments have failed. With proper medical guidance and adherence to the prescribed regimen, this targeted treatment supports better management of acute lymphoblastic leukemia and enhances the overall quality of care.
- Brand Name: Inonza
- Generic Name: Inotuzumab Ozogamicin
- Dosage Form: Injection
- Strength: As prescribed by oncologist
- Indication: Acute Lymphoblastic Leukemia (ALL)
- Drug Class: Monoclonal Antibody (CD22-directed ADC)
- Administration: Intravenous infusion
- Prescription Required: Yes
- Storage: Store in a refrigerator (2°C–8°C)
- Manufacturer: As per product packaging
